Evrysdi

Roche’s spinal muscular atrophy treatment Evrysdi shows continued benefit in children
PM Live
Fri, 06/14/24 - 11:38 am
Roche
SMA
Evrysdi
clinical trials
Roche’s Evrysdi offers sustained benefits in SMA extension trial in children
Clinical Trials Arena
Mon, 06/10/24 - 11:06 am
Roche
clinical trials
Evrysdi
SMA
PTC to sell spinal muscular atrophy drug royalties for $1B
BioPharma Dive
Thu, 10/19/23 - 11:34 am
PTC Therapeutics
spinal muscular atrophy
Evrysdi
Royalty Pharma
Majority of Newborn Babies With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Able to Sit Independently After 1 Year of Treatment
BioSpace
Wed, 10/4/23 - 09:41 am
Roche
Genentech
clinical trials
Evrysdi
SMA
Four-Year Follow-Up Data for Genentech’s Evrysdi Show Continued Increase in Number of Children With a Severe Form of Spinal ​Muscular ​Atrophy (SMA)​ Able to Sit, Stand and Walk
BioSpace
Mon, 07/3/23 - 11:38 am
Genentech
spinal muscular atrophy
SMA
Evrysdi
Roche puts pressure on SMA rivals with new FDA approval
Pharmaforum
Tue, 05/31/22 - 10:33 am
Roche
PTC Therapeutics
SMA
Evrysdi
FDA
New Three-Year Data for Genentech’s Evrysdi (risdiplam) Show Long-Term Improvements in Survival and Motor Milestones in Babies With Type 1 Spinal Muscular Atrophy (SMA)
BioSpace
Fri, 04/29/22 - 10:30 am
Genentech
Evrysdi
risdiplam
SMA
spinal muscular atrophy
Roche's aim to widen Evrysdi's label nabs speedy FDA review in young spinal muscular atrophy patients
Fierce Pharma
Tue, 01/25/22 - 10:54 am
Roche
Evrysdi
risdiplam
FDA
spinal muscular atrophy
Roche builds evidence for Evrysdi’s benefits in younger SMA patients
Pharmaforum
Fri, 09/24/21 - 12:01 pm
Roche
spinal muscular atrophy
Evrysdi
Citing 'less-than-optimal' outcomes for Roche's Evrysdi, Biogen launches high-dose Spinraza trial
Fierce Pharma
Thu, 09/16/21 - 10:52 am
Biogen
Spinraza
SMA
Roche
Evrysdi
spinal muscular atrophy
Zolgensma flatlines, but Spinraza isn’t the beneficiary
EP Vantage
Wed, 04/28/21 - 10:27 am
SMA
Biogen
Novartis
Roche
Spinraza
Zolgensma
Evrysdi
Evrysdi has ‘real world impact’ on lives of babies with severe SMA, says Roche
Pharmaforum
Thu, 04/15/21 - 10:02 am
Roche
Genentech
Evrysdi
SMA
From no drugs to 3: Patients with spinal muscular atrophy now face hard choices
BioPharma Dive
Mon, 10/5/20 - 11:39 pm
SMA
spinal muscular atrophy
Novartis
Zolgensma
Spinraza
Roche
Evrysdi